Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
15 hedge funds and large institutions have $1.1M invested in Titan Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
241% more call options, than puts
Call options by funds: $720K | Put options by funds: $211K
0% more funds holding
Funds holding: 15 → 15 (0)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
11% less capital invested
Capital invested by funds: $1.24M → $1.1M (-$138K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$165K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$74.9K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$65.8K |
| 4 |
VF
Virtu Financial
New York
|
+$60.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$162K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.14K |
| 3 |
Morgan Stanley
New York
|
-$4.57K |
| 4 |
WPA
Winning Points Advisors
Boca Raton,
Florida
|
-$3.65K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $746K | +$165K | +181 | +23% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $105K | +$39.3K | +43 | +45% |
|
|
ARTA
3
A.R.T. Advisors
New York
| $89K | +$65.8K | +72 | +164% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $63K | +$74.9K | +82 | New |
|
|
VF
5
Virtu Financial
New York
| $50K | +$60.3K | +66 | New |
|
6
Northern Trust
Chicago,
Illinois
| $19K | – | – | – |
|
|
WPA
7
Winning Points Advisors
Boca Raton,
Florida
| $15K | -$3.65K | -4 | -17% |
|
8
Bank of America
Charlotte,
North Carolina
| $8K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $2K | -$9.14K | -10 | -77% |
|
10
BlackRock
New York
| $2K | – | – | – |
|
|
11
Morgan Stanley
New York
| $1K | -$4.57K | -5 | -83% |
|
|
BCM
12
Blume Capital Management
Berkeley,
California
| $1K | – | – | – |
|
|
APA
13
American Portfolios Advisors
Holbrook,
New York
| $584 | – | – | – |
|
14
BNP Paribas Financial Markets
Paris,
France
| $1 | – | – | – |
|
|
PCM
15
Perkins Capital Management
Wayzata,
Minnesota
| – | -$162K | -151 | Closed |
|
TTNP Hedge Fund Activity: Q2 2019 in Review
15 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2019, worth a combined $1.1M — down 11% from $1.24M a quarter earlier.
Fund positioning in TTNP was balanced in Q2 2019: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $165K. The largest seller was Perkins Capital Management, exiting entirely with an estimated $162K sold.
- 15 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $1.1M of Titan Pharmaceuticals stock for Q2 2019, down 11% quarter-over-quarter.
- 2 funds opened new Titan Pharmaceuticals positions in Q2 2019 and 2 closed out, a net change of 0 holders.
- The largest Titan Pharmaceuticals buyer in Q2 2019 was Vanguard Group, an estimated $165K added.
- The largest Titan Pharmaceuticals seller in Q2 2019 was Perkins Capital Management, an estimated $162K sold.
Based on aggregated 13F filings for Q2 2019.